【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。

金融界01-01

上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2500601772?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-01 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500601772","market":"us","top_or_hot":-1,"title":"【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。","media":"金融界","content":"<html><body><div><span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购<a href=\"https://laohu8.com/S/HCM\">和黄医药</a>持有的上海和黄药业股权。<a href=\"https://laohu8.com/S/02607\">上海医药</a>拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【上海医药：拟收购上海和黄药业10%股权】上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">金融界</strong><span class=\"h-time small\">2025-01-01 16:33</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div><span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购<a href=\"https://laohu8.com/S/HCM\">和黄医药</a>持有的上海和黄药业股权。<a href=\"https://laohu8.com/S/02607\">上海医药</a>拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://24h.jrj.com.cn/2025/01/01163347020229.shtml\">金融界</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/01/01163347020229.shtml","article_id":"2500601772","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500601772","pubTimestamp":1735720425,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159830":"上海金","601607":"上海医药","BK4585":"ETF&股票定投概念","BK0028":"国家队","BK1197":"保健护理产品经销商","BK4007":"制药","BK1588":"回港中概股","00013":"和黄医药","BK0099":"上海本地重组","BK4588":"碎股","BK0188":"融资融券","BK1587":"次新股","BK0187":"一线龙头","BK1191":"制药","BK0175":"白马股","BK0184":"上海国资改革","BK0183":"MSCI概念","BK0209":"零售","BK0012":"证金概念","BK0196":"行业龙头","02607":"上海医药","BK0097":"医药电商","BK0020":"浦东新区","HCM":"和黄医药","BK4531":"中概回港概念"},"translate_title":"[Shanghai Pharmaceuticals: plans to acquire 10% equity of Shanghai Hutchison Pharmaceuticals] Shanghai Pharmaceuticals announced that the company plans to join the designated entity of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. to acquire the equity of Shanghai Hutchison Pharmaceuticals held by Hutchison Pharmaceuticals. Shanghai Pharmaceuticals intends to acquire 10% of the equity with its own funds of RMB 995 million. After the transaction is completed, Shanghai Pharmaceuticals will hold a total of 60% equity of Shanghai Hutchison Pharmaceuticals and consolidate it. This tr","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159830":1,"601607":1,"02607":1,"HCM":1,"00013":1},"content_text":"上海医药公告，公司计划联合上海金浦健服股权投资管理有限公司指定主体，收购和黄医药持有的上海和黄药业股权。上海医药拟以自有资金人民币9.95亿元收购其中的10%股权。交易完成后，上海医药将合计持有上海和黄药业60%股权，并对其实施并表。此次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500601772"}